Noopept

Noopept is a proline-containing dipeptide with nootropic and cognition-enhancing involvement (1). In cellular models, it has rescued α-synuclein amyloid toxicity (2). Noopept has also been shown to lead to the expression  of NGF and BDNF in rat hippocampus (3). It increases viability of hippocampal HT-22 neurons in a glutamate toxicity model (4). It also has been used in diabetes research, stabilizing blood glucose level and tolerance to glucose load in a streptozotocin diabetic rat model (5).

References:

1) Ostrovskaya et al. (2007), The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model; J. Psychopharmacol., 21 611

2) Jia et al. (2011), Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity; J. Mol. Biol., 414 699

3) Ostrovskaya et al. (2008), Noopept stimulates the expression of NGF and BDNF in rat hippocampus; Bull. Exp. Biol. Med., 146 334

4) Antipova et al. (2016), Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model; Bull. Exp. Biol. Med., 161 58

5) Ostrovskaya et al. (2014), Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes; Bull. Exp. Biol. Med., 156 342